Skip to main content
Premium Trial:

Request an Annual Quote

Clarified Precision Medicine, xCures Partner to Improve Clinical Decision Support Platforms

NEW YORK – Clarified Precision Medicine on Wednesday said it is partnering with health tech company xCures to provide artificial intelligence-based clinical support to oncologists and personalized patient treatment recommendations.

The two firms will use their platforms to analyze patient data and develop systems designed to advance the use of precision medicine through improved treatment optimization and integration of predictive analytics into precision oncology care.

Clarified will provide its specialized treatment recommendation system, which uses AI and insights from medical professionals. XCures will contribute its AI-driven platform designed to extract relevant medical information from patient data and improve access to medical records.

The companies will also collect patient data to enable retrospective and prospective data analysis aiming to further improve the delivery of precision medicine.

"This collaboration will enable us to deliver highly personalized and effective treatment recommendations, ultimately improving patient outcomes in precision oncology," xCures CEO Mika Newton said in a statement. "By combining our strengths, we can address the critical need for better access to precision medicine and support oncologists in making data-driven decisions that enhance patient care."

Earlier this year, Clarified raised $1.2 million in seed funding to advance its support platforms, including its treatment recommendation platform, ClarifiedSelect, and its virtual molecular tumor board platform, OncoGuardian. In 2022, Clarified partnered with VieCure to add its network of medical oncology experts to VieCure's clinical decision support platform.

XCures has also partnered with other health tech firms to advance precision medicine use. In 2022, xCures partnered with LifeOmic to scan hundreds of thousands of patients' medical records to potentially identify new cancer treatments. The firm has also collaborated with pharma companies Tyra Biosciences and Endeavor BioMedicines to support clinical trials.